IM92
/ Beijing Imunopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 11, 2022
Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
(clinicaltrials.gov)
- P1 | N=6 | Recruiting | Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.
CAR T-Cell Therapy • IO biomarker • New P1 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Cancer antigen 19-9 • CLDN18
1 to 1
Of
1
Go to page
1